Phosphorylcholine coating offers natural platelet preservation during cardiopulmonary bypass

被引:40
作者
De Somer, F
Van Belleghem, Y
Caes, F
François, K
Arnout, J
Bossuyt, X
Taeymans, Y
Van Nooten, G
机构
[1] State Univ Ghent Hosp, Ctr Heart, B-9000 Ghent, Belgium
[2] Univ Leuven, Ctr Mol & Vasc Biol, Louvain, Belgium
[3] Univ Hosp Leuven, Lab Med, Louvain, Belgium
来源
PERFUSION-UK | 2002年 / 17卷 / 01期
关键词
D O I
10.1191/0267659102pf526oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Return of blood activated by tissue factor is the main culprit for triggering the coagulation cascade. When this activated blood is diverted from the cardiopulmonary bypass (CPB) circuit, it becomes possible to evaluate the effect of surface treatment on platelet and complement activation. Twenty adult patients undergoing elective coronary artery bypass grafting (CABG) were randomly assigned either to a control group (n=10) or to a group in which the CPB circuit was completely coated with phosphorylcholine (n=10). Plasma concentrations of platelet factor 4 (PF4), beta-thromboglobulin (betaTG), C3, Cad, C4, TCC, thrombin generation, haptoglobin and free haemoglobin, as well as blood loss, were measured. No significant differences between the two groups were found for haemolysis and thrombin generation. The mean total release of PF4 and betaTG during CPB was 9338 +/- 17303 IU/ml/CPB and 3790 +/- 4104 IU/ml/CPB in the coated group versus 22192 13931 IU/ml/CPB (p=0.011) and 8040 +/- 3988 IU/ml/CPB (p=0.005) in the control group. Blood loss was 30% less in the coated group compared to the control group. Phosphorylcholine coating appears to have a favourable effect on blood platelets, which is most obvious after studying the changes during CPB. Clinically, this effect resulted in a 30% reduction in blood loss.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 17 条
[1]  
Bhujle R, 1997, ASAIO J, V43, pM739
[2]  
BOISCLAIR MD, 1993, BLOOD, V82, P3350
[3]   Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface [J].
De Somer, F ;
François, K ;
van Oeveren, W ;
Poelaert, J ;
De Wolf, D ;
Ebels, T ;
Van Nooten, G .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2000, 18 (05) :602-606
[4]   RETRANSFUSION OF SUCTIONED BLOOD DURING CARDIOPULMONARY BYPASS IMPAIRS HEMOSTASIS [J].
DEHAAN, J ;
BOONSTRA, PW ;
MONNINK, SHJ ;
EBELS, T ;
VANOEVEREN, W .
ANNALS OF THORACIC SURGERY, 1995, 59 (04) :901-907
[5]  
FINK PC, 1989, J CLIN CHEM CLIN BIO, V27, P261
[6]   Cardiopulmonary bypass circuit treated with surface-modifying additives: A clinical evaluation of blood compatibility [J].
Gu, YJ ;
Boonstra, PW ;
Rijnsburger, AA ;
Haan, J ;
van Oeveren, W .
ANNALS OF THORACIC SURGERY, 1998, 65 (05) :1342-1347
[7]   Hemocompatible cellulose dialysis membranes modified with phospholipid polymers [J].
Ishihara, K ;
Nakabayashi, N .
ARTIFICIAL ORGANS, 1995, 19 (12) :1215-1221
[8]  
JOHNSON AM, 1993, ARCH PATHOL LAB MED, V117, P29
[9]  
Lee JH, 1998, J BIOMED MATER RES, V41, P304, DOI 10.1002/(SICI)1097-4636(199808)41:2<304::AID-JBM16>3.3.CO
[10]  
2-F